

# Lasgrain™

Lasmiditan Tablet

## Presentation

Lasgrain™ 50: Each tablet contains Lasmiditan Hemisuccinate INN equivalent to Lasmiditan 50 mg.

Lasgrain™ 100: Each tablet contains Lasmiditan Hemisuccinate INN equivalent to Lasmiditan 100 mg.

## Description

Lasmiditan is a serotonin (5-HT) 1F receptor agonist. It binds with high affinity to the 5-HT<sub>1F</sub> receptor. It presumably exerts its therapeutic effects in the treatment of migraine through agonist effects at the 5-HT<sub>1F</sub> receptor; however, the precise mechanism is unknown.

## Indications

Lasmiditan is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use: It is not indicated for the preventive treatment of migraine.

## Dosage and Administration

The recommended dose of Lasmiditan is 50 mg, 100 mg, or 200 mg taken orally, as needed. No more than one dose should be taken in 24 hours and Lasmiditan should not be taken unless the patient can wait at least 8 hours between dosing and driving or operating machinery. A second dose of Lasmiditan has not been shown to be effective for the same migraine attack. The safety of treating an average of more than 4 migraine attacks in a 30-day period has not been established. Lasmiditan may be taken with or without food. Administer tablets whole; do not split, crush, or chew.

## Side-effects

The common side-effects of Lasmiditan include-dizziness, fatigue, paresthesia, sedation etc.

## Precautions

- **Driving Impairment:** Advise patients not to drive or operate machinery until at least 8 hours after taking each dose of Lasmiditan.
- **Central Nervous System (CNS) Depression:** Lasmiditan may cause CNS depression and should be used with caution if used in combination with alcohol or other CNS depressants.
- **Serotonin Syndrome:** Reactions consistent with serotonin syndrome were reported in patients treated with Lasmiditan. Discontinue Lasmiditan if symptoms of serotonin syndrome occur.
- **Medication Overuse Headache:** Detoxification may be necessary.

## Contraindications

N/A.

## Drug Interactions

- Lasmiditan may further lower heart rate when administered with heart rate lowering drugs.
- Avoid concomitant use with P-gp and Breast Cancer Resistant Protein (BCRP) substrates.

## Pregnancy and Lactation

Pregnancy: Lasmiditan may cause fetal harm when administered to a pregnant woman and it should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Lactation: There are no data on the presence of Lasmiditan in human milk, the effects of Lasmiditan on the breastfed infant, or the effects of Lasmiditan on milk production.

## Use in special population

Pediatric use: Safety and effectiveness of Lasmiditan has not been established in pediatric patients.

Geriatric use: Start at the low end of the dosing range.

Hepatic impairment: No dose adjustment is needed for patients with mild or moderate hepatic impairment. Use of Lasmiditan in severe hepatic impairment is not recommended.

## Overdose

In the event of overdose, Lasmiditan should be discontinued and general supportive treatment given until clinical toxicity has been diminished or resolved.

## Storage

Do not store above 30 ° C. Keep away from light and out of the reach of children.

## Commercial Pack

Lasgrain™ 50 : Each box contains 1 blister strip of 10 tablets.

Lasgrain™ 100 : Each box contains 1 blister strip of 4 tablets.